AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
SAN FRANCISCO, Dec. 21, 2017 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming J.P. Morgan 36th Annual Healthcare Conference in San Francisco, CA.
iRhythm’s management is scheduled to present on Wednesday, January 10, 2018 at 10:00am Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Investor Relations Contact:
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
Media Contact
Aaron Murphy
(415) 229-3331
[email protected]
